Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Trametinib · Mekinist

Small molecule · Inhibitor of MEK1 (MAP2K1) and MEK2 (MAP2K2) · developed by Novartis

Approved FDA, May 2013
1 Registered trials

What is Trametinib?

Trametinib is a reversible kinase inhibitor of MEK1 and MEK2, upstream regulators of the ERK pathway that drives cell proliferation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Mekinist
Drug type
Small molecule
Targets
MEK1 (MAP2K1), MEK2 (MAP2K2)
Mechanism
Inhibitor of MEK1 (MAP2K1) and MEK2 (MAP2K2)
Pathways
RAS/RAF/MEK/ERK (MAPK) pathway
Therapy area
Oncology
Developer
Novartis
In trials of
CLDX
FDA status
Approved as Mekinist (May 29, 2013), NDA204114 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of May 7, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03580382 Phase 1/2 Melanoma Terminated CLDX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Melanoma

Other drugs acting on MAP2K1 / MAP2K2

Mirdametinib FDA approved Atebimetinib Phase 3 IMM-6-415 Phase 1/2 PAS-004 Phase 1

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.